Abstract
Cardiovascular disease is the leading cause of death in patients with chronic kidney disease (CKD) or even those after renal transplantation. Radionuclide myocardial perfusion imaging (MPI) is an available way to predict cardiac events and make risk stratification for CKD patients with cardiovascular diseases. Early detection and individualized treatment of patients with high-risk of cardiac events by MPI can prevent myocardial infarction and heart failure, thus improving the survival rate of this population. This article reviews the application of MPI in patients with CKD. Key words: Nephrosis; Chronic disease; Myocardial perfusion imaging; Trends
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Chinese Journal of Nuclear Medicine and Molecular Imaging
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
